NEW YORK, July 30, 2018 – Levi & Korsinsky, LLP announces a class action on behalf of all persons or entities who purchased or otherwise acquired securities of Tetraphase Pharmaceuticals, Inc. (NASDAQ: TTPH) (1) Pursuant and/or traceable to the July 2017 Secondary Offering and/or (2) between March 8, 2017 and February 13, 2018. You are hereby notified that the Tetraphase Pharmaceuticals class action lawsuit has been commenced in the United States District Court for the Southern District of New York . To get more information about the TTPH lawsuit click here: http://www.zlk.com/pslra-d/tetraphase-pharmaceuticals-inc or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

The Tetraphase Pharmaceuticals Class Action complaint alleges that: (1) Tetraphase was increasing the patient enrollment in its IGNITE3 trial from 1,000 patients to 1,200 patients to meet the trial’s primary endpoints; (2) the enrollment of more patients in the trial indicated that the existing population was inadequate to meet the trial’s primary endpoints; and (3) consequently, Defendants’ statements about Tetraphase’s business, operations, and prospects, were materially false and/or misleading and/or lacked a reasonable basis.

If you suffered a loss in Tetraphase Pharmaceuticals you have until September 25, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.